School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China; Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Pharmacol Res. 2019 Dec;150:104500. doi: 10.1016/j.phrs.2019.104500. Epub 2019 Oct 16.
Ketone bodies are traditionally viewed as metabolic substrates in carbohydrate restriction and are applied in the treatment of epilepsy and other neurodegenerative diseases. Recently, people have paid more attention to its application in the treatment for cancers. Compared to normal cells, cancer cells maintain a higher level of reactive oxygen species (ROS) due to the dysfunctional oxidative phosphorylation and they highly rely on glucose for glycolysis and pentose phosphate pathway (PPP) to against the oxidative stress. Based on tumor metabolism, ketogenic diets (low-carbohydrate, high-fat, and moderate protein) or ketone supplementation, as non-toxic therapeutic approaches, showed a positive therapeutic advantage in a broad range of malignancies. This review summarizes the multi-dimensional roles of ketone bodies in cancer biology and discusses the potential underlying mechanism in the inhibition of tumor growth.
酮体传统上被视为碳水化合物限制时的代谢底物,并应用于癫痫和其他神经退行性疾病的治疗。最近,人们越来越关注其在癌症治疗中的应用。与正常细胞相比,由于氧化磷酸化功能障碍,癌细胞中活性氧(ROS)水平保持较高,并且它们高度依赖葡萄糖进行糖酵解和磷酸戊糖途径(PPP)以对抗氧化应激。基于肿瘤代谢,生酮饮食(低碳水化合物、高脂肪和适量蛋白质)或酮补充剂作为无毒治疗方法,在广泛的恶性肿瘤中显示出积极的治疗优势。本综述总结了酮体在癌症生物学中的多维作用,并讨论了抑制肿瘤生长的潜在机制。